Gastrointestinal ulcer therapeutic - Intec Pharma

Drug Profile

Gastrointestinal ulcer therapeutic - Intec Pharma

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator Intec Pharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Gastrointestinal ulcer

Most Recent Events

  • 10 Mar 2016 Intec Pharma completes a phase I trial in Gastrointestinal ulcer (In volunteers)
  • 29 Jan 2016 Investigation in Gastrointestinal ulcer (In volunteers, Prevention) (PO)
  • 08 Dec 2015 Phase-I clinical trials in Gastrointestinal ulcer (In volunteers) (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top